The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Condition: Dry Eye Interventions: Drug: Reproxalap Ophthalmic Solution (0.25%) QID; Drug: Vehicle Ophthalmic Solution QID; Drug: Reproxalap Ophthalmic Solution (0.25%) QID to BID; Drug: Vehicle Ophthalmic Solution QID to BID Sponsor: Aldeyra Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials